INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

Core Viewpoint - An investigation is underway regarding Pfizer's Board of Directors for potential breaches of fiduciary duties related to the marketing and sale of Depo-Provera, a contraceptive injectable [1][2]. Group 1: Investigation Details - The investigation by Berger Montague focuses on whether Pfizer's Board of Directors adequately oversaw the marketing and sale of Depo-Provera, which is used for contraception and treating endometriosis [2]. - There are reported concerns about potential links between long-term use of Depo-Provera and an increased risk of meningiomas, a type of brain tumor [2]. Group 2: Company Background - Berger Montague has been involved in shareholder litigation since its founding in 1970 and has represented both individual and institutional investors for over five decades [3]. - The firm operates in multiple locations across the United States, including Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, and Chicago [3].